Department of Clinical Sciences College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
Department of Biostatistics and Medical Informatics School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Vet Ophthalmol. 2021 Mar;24(2):156-168. doi: 10.1111/vop.12855. Epub 2020 Dec 29.
Canine sudden acquired retinal degeneration syndrome (SARDS) causes blindness for which there are no proven effective treatments. We aimed to clarify the time to vision loss, treatment response/side effects, and prognosis for life in dogs with SARDS.
An online questionnaire was administered to owners of dogs with a historical diagnosis of SARDS. Mortality data were compared with a published purebred reference population. Select parameters were analyzed statistically using general linear model with least square means, two-sample t tests, and chi-squared or Fisher's exact tests.
Responses from owners that stated that their dog visited an ophthalmologist and had electroretinography performed (n = 434) were analyzed. The majority of owners (65.4%) reported the time from vision disturbance to complete vision loss as <2 weeks; 19.4% reported >4 weeks. Onset of systemic clinical signs to complete vision loss was >4 weeks in 44.5% of responses. A higher proportion of owners reported some vision recovery with combination treatment (14.4%) compared with monotherapy (3.2%, P = .0004). Side effects of treatment were commonly reported. Dogs with SARDS did not have a shorter lifespan than the reference population but had higher incidence of kidney disease (P = .0001) and respiratory disease (P = .0004) at death.
Dogs with SARDS have a rapid onset of vision loss. In the owner's opinion, treatment is unlikely to restore vision and is associated with systemic side effects. The potential for systemic pathologies that arise after SARDS diagnosis warrants further study.
犬获得性突发性视网膜变性综合征（SARDS）可导致失明，目前尚无有效的治疗方法。我们旨在明确 SARDS 犬的视力丧失时间、治疗反应/副作用和预后。
向患有 SARDS 历史诊断的犬主人发放在线问卷。将死亡率数据与已发表的纯种参考人群进行比较。使用最小二乘均值、双样本 t 检验、卡方或 Fisher 精确检验的一般线性模型对选定参数进行统计分析。
对表示其犬曾就诊于眼科医生并进行视网膜电图检查的主人（n=434）的回复进行了分析。大多数主人（65.4%）报告称从视力障碍到完全失明的时间<2 周；19.4%报告>4 周。44.5%的病例报告称，全身性临床症状到完全失明的发作时间>4 周。与单一疗法（3.2%，P=0.0004）相比，联合治疗的主人报告有更多的视力恢复（14.4%）。治疗的副作用通常会被报告。SARDS 犬的寿命并不比参考人群短，但在死亡时肾脏疾病（P=0.0001）和呼吸道疾病（P=0.0004）的发病率更高。
SARDS 犬的视力丧失迅速。在主人看来，治疗不太可能恢复视力，并且与全身性副作用有关。SARDS 诊断后出现的全身疾病的可能性需要进一步研究。
